Replies to post #212294 on Biotech Values

[DewDiligence]

GKTX.PA—Did you make this post due to some specific issue you see in trying to develop an oral small molecule inhibitor against NOX? Is it a concern with the target itself? Concern with being able to hit the target? Or more a concern that this is a completely unproven target and approach?

None of the above, specifically. My quip at the bottom of #msg-127378262 was triggered by the sheer enormity of the company’s mission, as stated in the quoted text—especially this sentence:

Genkyotex’s therapeutic approach is based on a selective inhibition of NOX enzymes, which drive a broad range of disease processes, including fibrosis, inflammatory pain, angiogenesis, cancer growth, and neurodegeneration.